Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed May 8, 2013 · 10-Q · 38 days after period end · 0001483813-13-000051
| Metric | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|
| Revenue | $11.83M | $7.44M | $7.54M |
| Net Income | -$19.29M | -$15.12M | -$9.64M |
| EPS Diluted | -$0.17 | -$0.14 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
ended Mar 31, 2013 · filed May 8, 2013 · 38 d after period end
